LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Inicio・Lista de Acciones・Amarin Corp PLC ADR

Amarin Corp PLC ADR

Cerrado

0.58

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.57

Máximo

0.59

Métricas clave
By Trading Economics
Ingresos	11M 1.5M
Ventas	11M 67M
BPA	0.01
Margen de beneficio	2.252
EBITDA	13M 237K

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 meses	+69.49 upside

Dividendos
By Dow Jones
Próximas Ganancias	30 oct 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-11M 246M
Apertura anterior	0.58
Cierre anterior	0.58

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

0.59 / 0.6095 Soporte y Resistencia

Amarin Corp PLC ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2024, 23:10 UTC

Principales Noticias

Bank of Canada Welcomes 2% Inflation, Pivoting Focus to Growth

17 sept 2024, 16:37 UTC

Ganancias

Correction to Walmart Headlines on Aug. 15

17 sept 2024, 16:21 UTC

Adquisiciones, fusiones, absorciones

Generali Agrees to Sale of Turkish Business

17 sept 2024, 16:03 UTC

Ganancias

Correction to Estee Lauder Headline on Aug. 19

17 sept 2024, 21:45 UTC

Principales Noticias

UAW Clashes With Jeep Maker Stellantis Over Promised Factory Work -- WSJ

17 sept 2024, 21:20 UTC

Principales Noticias

Fed's 'Reverse Repo' Balance Fell to Lowest in Over 3 Years. Why It Matters. -- Barrons.com

17 sept 2024, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2024, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2024, 20:38 UTC

Principales Noticias

The Stock Market Is Priced for Middling Returns No Matter What the Fed Does -- Barrons.com

17 sept 2024, 20:24 UTC

Principales Noticias

U.S. Stocks Pare Gains; Traders Betting on Big Fed Cut -- WSJ

17 sept 2024, 20:05 UTC

Principales Noticias

Meta Extends Ray-Ban Partnership; Zuckerberg Says Glasses 'Next Major Tech Platform' -- IBD

17 sept 2024, 20:00 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- 2nd Update

17 sept 2024, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

17 sept 2024, 19:28 UTC

Principales Noticias

U.S. Stocks Give Up Gains; Traders Still Betting on Big Fed Cut -- WSJ

17 sept 2024, 19:10 UTC

Principales Noticias

Forget the Fed. This is the Stock Market's Biggest Risk. -- Barrons.com

17 sept 2024, 19:08 UTC

Charlas de Mercado

Oil Futures Rise on Renewed Middle East Tensions -- Market Talk

17 sept 2024, 18:21 UTC

Charlas de Mercado

Gold Down As Investors Await Fed Decision -- Market Talk

17 sept 2024, 18:06 UTC

Charlas de Mercado

Barrick CEO Argues Valuation Case as Company Targets Growth -- Market Talk

17 sept 2024, 17:36 UTC

Charlas de Mercado

Steel Industry Challenges on Display Amid Warning from Nucor -- Market Talk

17 sept 2024, 17:32 UTC

Charlas de Mercado

Oil Futures Press Higher On Lebanon, Fed Watch -- Market Talk

17 sept 2024, 17:07 UTC

Charlas de Mercado

Canada Housing Construction To Remain Weak Through 2024 -- Market Talk

17 sept 2024, 17:04 UTC

Adquisiciones, fusiones, absorciones

Workday Is Buying Evisort in Move Into AI-Based Document Intelligence -- Barrons.com

17 sept 2024, 17:03 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- Update

17 sept 2024, 16:43 UTC

Charlas de Mercado

Treasury Yields Rise As U.S. Indicators Show Strength -- Market Talk

17 sept 2024, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2024, 16:11 UTC

Principales Noticias

JPMorgan in Talks With Apple to Take Over Credit Card From Goldman -- WSJ

17 sept 2024, 16:04 UTC

Principales Noticias

U.S. Stock Indexes Rise; Traders Still Betting on Big Fed Cut -- WSJ

17 sept 2024, 15:57 UTC

Charlas de Mercado

Bank of Canada 'Completely Behind the Curve' -- Market Talk

17 sept 2024, 15:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2024, 15:50 UTC

Charlas de Mercado

Hitting 2% Inflation Not Enough to Justify Faster, Deeper Canada Rate Cuts -- Market Talk

Comparación entre iguales

Cambio de precio

Amarin Corp PLC ADR Esperado

Precio Objetivo

By TipRanks

69.49% repunte

Estimación a 12 meses

Media 1 USD 69.49%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amarin Corp PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Amarin Corp PLC ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.59 / 0.6095Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amarin Corp PLC ADR

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.